公开(公告)号：US20190338005A1

公开(公告)日：2019-11-07

申请号：US16519987

申请日：2019-07-23

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Claudia Wagner ,  Julia Leibold ,  Colette Song

IPC: C07K14/47 ,  A61K39/00 ,  C07K14/725 ,  C07K14/74 ,  C12N5/0783 ,  A61K35/17 ,  C07K16/30 ,  C07K16/28 ,  A61P35/00 ,  G16B20/20 ,  G01N33/574 ,  C12Q1/6886

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US10155032B2

公开(公告)日：2018-12-18

申请号：US15638072

申请日：2017-06-29

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Phillip Mueller ,  Julia Leibold ,  Valentina Goldfinger

IPC: A61K38/00 ,  A61K39/00 ,  C07K14/47 ,  C07K14/725 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574 ,  G01N33/68

Abstract: A method of treating a patient who has prostate cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has prostate cancer. A method of treating a patient who has prostate cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the prostate cancer.

公开(公告)号：US11786584B2

公开(公告)日：2023-10-17

申请号：US17320929

申请日：2021-05-14

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Phillip Mueller ,  Julia Leibold ,  Valentina Goldfinger

IPC: A61K39/00 ,  C07K14/47 ,  C07K14/725 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574 ,  G01N33/68 ,  A61K38/00

CPC classification number: A61K39/0011 ,  C07K14/47 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/30 ,  C12N5/0636 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/5748 ,  G01N33/6848 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K2319/00 ,  C12N2310/16 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/57407 ,  G01N2570/00 ,  G01N2800/52

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor associated T-cell peptide epitopes, alone or in combination with other tumor associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US11065315B2

公开(公告)日：2021-07-20

申请号：US17017281

申请日：2020-09-10

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Phillip Mueller ,  Julia Leibold ,  Valentina Goldfinger

IPC: A61K39/00 ,  C07K14/47 ,  C07K14/725 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574 ,  G01N33/68 ,  A61K38/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US10662233B2

公开(公告)日：2020-05-26

申请号：US16714112

申请日：2019-12-13

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Claudia Wagner ,  Julia Leibold ,  Colette Song

IPC: A61K35/17 ,  C07K14/47 ,  G16B20/20 ,  A61K39/00 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12Q1/6886 ,  G01N33/574 ,  A61P35/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US10577402B2

公开(公告)日：2020-03-03

申请号：US16519959

申请日：2019-07-23

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Claudia Wagner ,  Julia Leibold ,  Colette Song

IPC: C07K14/47 ,  A61K35/17 ,  C07K16/28 ,  C12N5/0783 ,  C07K14/74 ,  A61P35/00 ,  C07K16/30 ,  G16B20/20 ,  G01N33/574 ,  C12Q1/6886 ,  A61K39/00 ,  C07K14/725

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US10550167B2

公开(公告)日：2020-02-04

申请号：US16519987

申请日：2019-07-23

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Claudia Wagner ,  Julia Leibold ,  Colette Song

IPC: A61K35/17 ,  C07K14/47 ,  C07K14/725 ,  C07K14/74 ,  C12N5/0783 ,  C07K16/30 ,  C07K16/28 ,  A61P35/00 ,  G16B20/20 ,  G01N33/574 ,  C12Q1/6886 ,  A61K39/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US10526389B2

公开(公告)日：2020-01-07

申请号：US16520003

申请日：2019-07-23

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Claudia Wagner ,  Julia Leibold ,  Colette Song

IPC: A61K39/00 ,  C07K14/47 ,  C07K14/725 ,  C07K14/74 ,  C12N5/0783 ,  A61K35/17 ,  C07K16/30 ,  C07K16/28 ,  A61P35/00 ,  G16B20/20 ,  G01N33/574 ,  C12Q1/6886

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US10478480B2

公开(公告)日：2019-11-19

申请号：US16385225

申请日：2019-04-16

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Phillip Mueller ,  Julia Leibold ,  Valentina Goldfinger

IPC: A61K39/00 ,  G01N33/574 ,  C12Q1/6886 ,  C12N5/0783 ,  C07K16/30 ,  C07K14/47 ,  C12N15/115 ,  C07K14/725 ,  G01N33/68 ,  A61K38/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US10376568B2

公开(公告)日：2019-08-13

申请号：US16210330

申请日：2018-12-05

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Phillip Mueller ,  Julia Leibold ,  Valentina Goldfinger

IPC: A61K38/00 ,  A61K39/00 ,  C07K14/47 ,  C07K14/725 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574 ,  G01N33/68

Abstract: A method of treating a patient who has prostate cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has prostate cancer. A method of treating a patient who has prostate cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the prostate cancer.